New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

2 nd Annual Essentials in Primary Care
Fall Conference
Friday, November 11, 2011
Dabigatran- Pradaxa
• DOSING: Recommended Dose for patients with creatinine
clearance (CrCl) >30 mL/min, the recommended dose of
dabigatran is 150 mg taken orally, twice daily, with or without
food. For patients with CrCl 15-30 mL/min, or patients 75 years
of age or older the recommended dose is 75 mg twice daily
•
– Instruct patients to swallow the capsules whole. Breaking,
chewing, or emptying the contents of the capsule can result
in increased exposure.
– Pradaxa capsules will hydrolyze over time when exposed to
humidity, causing a breakdown of active ingredient, and
rendering the medication less effective. Pradaxa is
packaged in a 30-day supply bottle with a desiccant cap or
in unit-of-use blister packaging to minimize product
breakdown from moisture.
Rivaroxaban – Xarelto
by Bayer HealthCare AG and Janssen Pharmaceuticals
Rivaroxaban exhibits a linear pharmacokinetic
relationship with a rapid onset of action, resulting
in maximal factor Xa inhibition in approximately 3
hours. Maintenance of the anti–factor Xa effect
lasted 8 to 12 hours, depending on the dose of
rivaroxaban.
Terminal half-life of rivaroxaban is approximately 9
hours in adults and 12 hours in elderly patients
(older than 65 years of age). Elimination of
rivaroxaban occurs by multiple routes: renal (onethird
is excreted unchanged), biliary/fecal, and
hepatic (through CYP-450 3A4). Renal function
impairment may influence elevated plasma
concentrations and increased anti-Xa activity;
therefore, dose adjustments may be required
Wayne Weart
New Drug Update Part I